CLAIMS

~~1. A graphene nanomaterial selected from graphene nanofibers, wherein the graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 μm or smaller in number of particle and a dv(90) of 80.00 μm or smaller in volume particle, as measured by laser diffraction particle analyzer.~~

~~2. The graphene nanomaterial according to claim 1, wherein its BET specific surface area is comprised between 100 and 500 m^2/g.~~

~~3. The graphene nanomaterial as defined in claim 2, wherein its BET specific surface area is between 300-350 m^2/g.~~

~~4. The graphene nanomaterial as defined in claim 1, wherein its pore volume is between 0.35-0.40 cm^3/g.~~

~~5. The graphene nanomaterial as defined in claim 1 wherein its BET specific surface area is between 300-350 m^2/g and its pore volume is between 0.35-0.40 cm^3/g.~~

~~6. The graphene nanomaterial according to any of claims 1 to 5, wherein the impurities in the nanomaterial are less than 0.01% by weight.~~

~~7~~1. A graphene nanomaterial ~~according to any of claims 1 to 6,~~ for use as a medicament, wherein the graphene nanomaterial is selected from graphene nanofibers; and wherein the graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 μm or smaller in number of particle and a dv(90) of 80.00 μm or smaller in volume particle, as measured by laser diffraction particle analyzer.

2. The graphene nanomaterial for use as a medicament according to claim 1, wherein the BET specific surface area of the graphene nanomaterial is comprised between 100 and 500 m^2/g.

3. The graphene nanomaterial for use as a medicament according to claim 2, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g.

4. The graphene nanomaterial for use as a medicament according to claim 1, wherein the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

5. The graphene nanomaterial for use as a medicament according to claim 1, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g and the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

6. The graphene nanomaterial for use as a medicament according to any one of claims 1 to 5, wherein the impurities in the graphene nanomaterial is less than 0.01% by weight.

~~8~~7. ~~A~~ The graphene nanomaterial for use as a medicament according to any one of claims 1 to 6, ~~for use~~ in the treatment of wounds, scars, eczema, skin burns, skin ulcers or other skin les~~s~~ions.

~~9~~8. ~~A~~ The graphene nanomaterial for use as a medicament according to ~~any of~~ claim~~s 1 to 6~~7, ~~for use according to claim 8~~ in the treatment of skin les~~s~~ions produced by psoriasis, diabetes, cancer, infections, acne or decreased circulation of blood.

~~10~~9. A pharmaceutical composition comprising a graphene nanomaterial ~~product as defined in any of claims 1 to 6~~ and a pharmaceutically acceptable excipient,

wherein the graphene nanomaterial is selected from graphene nanofibers; and

wherein the graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 μm or smaller in number of particle and a dv(90) of 80.00 μm or smaller in volume particle, as measured by laser diffraction particle analyzer.

10. The pharmaceutical composition according to claim 9, wherein the BET specific surface area of the graphene nanomaterial is comprised between 100 and 500 m^2/g.

11. The pharmaceutical composition as defined in claim 10, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g.

12. The pharmaceutical composition as defined in claim 9, wherein the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

13. The pharmaceutical composition as defined in claim 9, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g and the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

14. The pharmaceutical composition according to any one of claims 9 to 13, wherein the impurities in the graphene nanomaterial is less than 0.01% by weight.

~~11~~15. ~~A~~ The pharmaceutical composition according to any one of claims 9 to 14 ~~10~~, wherein the composition is suitable for topical use.

~~12~~16. ~~A~~ The pharmaceutical composition according to claim ~~11~~ 15, wherein the composition ~~it~~ is in a form selected from a cream, an ointment, a microemulsion, a gel, an emulsion-gel, a paste, a foam, a tincture, a patch, a bandage, a membrane, a matrix or a transdermal delivery system~~s~~.

~~13~~17. A pharmaceutical composition according to claim ~~12~~ 16, wherein the composition~~it~~ is a hydrogel or a cream.

~~14. A method to prepare the product as defined in any of claims 1-6 from raw graphene nanofibers, comprising the steps of:~~

~~a) Purifying the raw graphene material, preferably using a strong acid, to remove any metal or impurity present in the graphene raw material,~~

~~b) Reducing the particle size of the purified graphene nanomaterial, preferably through an exfoliation process, to a particle size distribution having a dn(90) of 0.60 pm or smaller in number of particle and a dv(90) of 80.00 pm or smaller in volume particle, as measured by laser diffraction particle analyzer,~~

~~c) Optionally subjecting the obtained product to a depyrogenization process.~~